RNA pathway links FTO to inflammatory podocyte damage in diabetic kidney disease

Researchers have identified a molecular cascade in which FTO stabilises EGR1 messenger RNA, triggering STING1-driven inflammation and worsening damage to the kidney’s filtration barrier.

A study published in Cellular and Molecular Life Sciences has identified a molecular pathway that may help explain how diabetes damages the kidney’s filtering units, and why podocyte injury is such a pivotal step in diabetic kidney disease. According to the research, the RNA demethylase FTO appears to stabilise EGR1 messenger RNA by removing m6A chemical marks, allowing more of the EGR1 protein to accumulate in podocytes. The authors report that higher EGR1 levels in podocytes from people with diabetic kidney disease were associated with poorer kidney function and greater urinary protein loss, both markers of more advanced damage.

Podocytes are specialised cells that form part of the kidney’s filtration barrier. When they are injured, protein can leak into the urine and scarring can accelerate. The new work suggests that in a high-glucose environment, EGR1 rises and helps drive inflammatory injury in these cells. Silencing EGR1 in cultured human podocytes eased that damage, while increasing it made the injury worse, strengthening the case that the gene is not merely a bystander but part of the disease process.

The mechanism becomes more striking further down the chain. The researchers found that EGR1 binds to the promoter region of STING1, the gene for stimulator of interferon genes 1, and increases its activity. That turns on the STING1/TBK1/NF-κB pathway, a well-known inflammatory signalling route. In practical terms, the study describes a cascade in which an RNA modification helps preserve a transcript, that transcript boosts a transcription factor, and the transcription factor then switches on an inflammatory programme that damages podocytes from within.

The team also tested the pathway in diabetic mice. Using virus-based genetic tools directed at podocytes, they reduced or increased EGR1 in the cells. When EGR1 was removed, podocyte and glomerular injury improved and proteinuria eased. When it was increased, kidney damage became worse. Those results give the study its strongest evidence that EGR1 sits at a meaningful point in the disease process, at least in animal models.

The findings also fit into a broader body of research suggesting that FTO may influence diabetic kidney disease through several routes. Other recent studies indexed by PubMed have linked the enzyme to NLRP3, ATF3, ACC1 and SAA2, each tied to different forms of podocyte stress, inflammation or metabolic injury. Taken together, those reports suggest FTO may be a broader regulator of kidney damage than previously thought, rather than a one-off molecular oddity. That does not yet make it a proven drug target, however. The human data in the new study are still correlational, and the mouse work, while persuasive, cannot fully reproduce human disease.

Even so, the study adds an important piece to the puzzle of diabetic kidney disease, which remains one of the main causes of kidney failure worldwide. Current treatment still relies heavily on blood-glucose control, blood-pressure management and therapies that block the renin-angiotensin system, with newer drugs such as SGLT2 inhibitors improving outcomes for many patients. Yet a substantial number still progress towards dialysis or transplantation. By mapping a pathway from FTO and m6A RNA marking to EGR1 and then to STING1-driven inflammation, the researchers have outlined a possible route for future therapies aimed more directly at the kidney’s filtering cells.